GO:0051008 Hsp27 protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051008 (Hsp27 protein binding) is a molecular function defined as binding to Hsp27 proteins, a lightweight heat shock protein.
• Hsp27 (HSPB1) interacts with diverse client proteins including tau, I-kappaBalpha, hic-5/ARA55, and VDAC3, regulating their stability and function.
• Hsp27 binding is dynamically regulated by phosphorylation and competing protein-protein interactions, particularly in stress responses.
• Dysregulated Hsp27 interactions contribute to cancer progression, chemoresistance, and neurodegenerative proteinopathies.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect the causal roles of Hsp27-client interactions.
• EDITGENE provides end-to-end services for generating and screening Hsp27 interaction models, accelerating target validation.
Description
Hsp27 protein binding (GO:0051008) is a molecular function that describes the physical interaction between a protein and Hsp27 (also known as HSPB1), a small heat shock protein. Hsp27 is a ubiquitously expressed chaperone that binds to a wide array of client proteins, thereby modulating their folding, stability, and activity. This binding activity is central to cellular stress responses, apoptosis regulation, and protein homeostasis. Researchers study Hsp27 protein binding to understand how cells cope with proteotoxic stress and how this process goes awry in diseases such as cancer and neurodegeneration. The interaction between Hsp27 and its clients is not static; it is regulated by phosphorylation and by competition with other binding partners, making it a dynamic and context-dependent function. Given its broad impact, Hsp27 protein binding is a focal point for therapeutic intervention and biomarker discovery.
Hsp27 protein binding At A Glance
| GO ID | GO:0051008 |
|---|---|
| GO term | Hsp27 protein binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to Hsp27 proteins, a lightweight heat shock protein |
| Major clients | Tau, I-kappaBalpha, hic-5/ARA55, VDAC3, ceramide-related proteins |
| Regulation | Phosphorylation of Hsp27, competing protein-protein interactions |
| Disease relevance | Cancer, neurodegeneration, inflammatory disorders |
| Research methods | Co-immunoprecipitation, CRISPR knockout, proteomics, imaging |
What Is GO:0051008?
Hsp27 protein binding (GO:0051008) is the molecular function of selectively interacting with Hsp27 proteins, which are lightweight heat shock proteins. This binding event is a non-covalent, reversible interaction that typically involves the formation of protein complexes. It is a key mechanism by which Hsp27 exerts its chaperone-like and signaling functions, influencing the fate of client proteins.
Why Is Hsp27 protein binding Important in Cell Biology?
Hsp27 protein binding is critically important because it governs the stability and function of numerous client proteins involved in cell survival, apoptosis, and stress resistance. For example, Hsp27 binding to I-kappaBalpha regulates NF-kappaB signaling and proteasomal degradation, linking this function to inflammation and cancer. In neurodegeneration, Hsp27 binding to tau modulates tau aggregation, a hallmark of Alzheimer's disease. Moreover, Hsp27 interactions with mitochondrial proteins such as VDAC3 influence ferroptosis and drug resistance in breast cancer. Thus, understanding Hsp27 protein binding provides mechanistic insights into disease pathogenesis and offers opportunities for therapeutic targeting.
• Regulates protein homeostasis by preventing aggregation of client proteins.
• Modulates apoptosis through interactions with I-kappaBalpha and other signaling molecules.
• Influences cancer chemoresistance, as shown for VDAC3 in HER2-low breast cancer.
• Contributes to neurodegenerative disease by binding to tau and affecting its aggregation.
• Controls mitochondrial function via ceramide generation.
• Participates in lysophagy and cellular stress responses through p38 MAPK-dependent phosphorylation.
• Serves as a biomarker for astrocyte differentiation and placental multipotent cells.
• Provides a target for CRISPR-based functional genomics to identify novel interaction partners.
• Enables high-throughput screening for modulators of protein-protein interactions.
• Links heat shock response to ubiquitin-proteasome system.
What Happens During Hsp27 protein binding?
Client recognition and binding
In simple terms: Hsp27 grabs onto specific partner proteins to keep them stable or change their behavior.
Hsp27 binds to a diverse set of client proteins through its conserved alpha-crystallin domain. For instance, Hsp27 directly binds to tau, and this interaction competes with other tau-binding proteins, thereby regulating tau's fate. Similarly, Hsp27 binds to I-kappaBalpha, an inhibitor of NF-kappaB, and this binding is involved in its proteasomal degradation. The binding is often mediated by hydrophobic patches exposed on client proteins under stress conditions.
Phosphorylation-dependent regulation
In simple terms: Chemical tags on Hsp27 can switch its binding on or off.
Hsp27 phosphorylation, particularly by p38 MAPK, modulates its interaction with clients. For example, lysosomal damage triggers a p38 MAPK-dependent phosphorylation cascade that promotes lysophagy via Hsp27, indicating that phosphorylation is required for certain binding events. This phosphorylation can alter Hsp27's oligomeric state and its affinity for specific partners.
Competition and complex formation
In simple terms: Other proteins can compete with Hsp27 for the same binding site, changing the outcome.
Competing protein-protein interactions regulate the binding of Hsp27 to its client tau. Freilich et al. showed that other proteins can displace Hsp27 from tau, affecting tau aggregation. This competition ensures a dynamic equilibrium that can be shifted under pathological conditions.
Downstream functional consequences
In simple terms: Once bound, Hsp27 can change what the client protein does, such as altering its degradation or activity.
Binding of Hsp27 to I-kappaBalpha leads to its ubiquitination and proteasomal degradation, thereby activating NF-kappaB. In mitochondria, Hsp27 binding to VDAC3 impedes its ubiquitination, alleviating ferroptosis and conferring resistance to trastuzumab deruxtecan in HER2-low breast cancer. Hsp27 also controls mitochondrial function by modulating ceramide generation.
Key Genes Involved in GO:0051008 Hsp27 protein binding
The following genes and proteins are central to Hsp27 protein binding, either as Hsp27 itself or as its interaction partners.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HSPB1 (Hsp27) | Small heat shock protein; binds client proteins | Central to GO:0051008; target for knockout/overexpression |
| MAPT (Tau) | Microtubule-associated protein; Hsp27 client | Neurodegeneration; binding competition regulates aggregation |
| NFKBIA (I-kappaBalpha) | Inhibitor of NF-kappaB; Hsp27 client | Inflammation and cancer; Hsp27 binding promotes degradation |
| HIC5 (ARA55) | Focal adhesion protein; Hsp27 binding partner | Cell adhesion and signaling; identified as Hsp27 interactor |
| VDAC3 | Mitochondrial porin; Hsp27 client | Ferroptosis and drug resistance in breast cancer |
| S100A16 | Calcium-binding protein; co-regulated with HSP27 | Astrocyte differentiation from placenta-derived multipotent cells |
| FLNC | Filamin C; interacts with HSPB7, related to Hsp27 family | Muscle function; dimerisation regulated by HSPB7 |
| HSPB7 | Small heat shock protein; regulates FLNC | Cardiomyopathy; related to Hsp27 family |
| p38 MAPK (MAPK14) | Kinase that phosphorylates Hsp27 | Stress response; required for lysophagy |
| CERamide-related enzymes | Enzymes in ceramide generation | Mitochondrial function controlled by Hsp27 |
| Ubiquitin | Protein modifier; Hsp27 is a ubiquitin-binding protein | Proteasomal degradation of I-kappaBalpha |
| Proteasome subunits | Degrade ubiquitinated proteins | Hsp27 involvement in I-kappaBalpha degradation |
| HSPB1 mutants | Phosphorylation-deficient or -mimetic forms | Dissect phosphorylation-dependent binding |
| Tau mutants | Aggregation-prone forms | Study competition with Hsp27 |
| VDAC3 mutants | Ubiquitination-deficient forms | Ferroptosis resistance |
| HIC5 mutants | Binding-deficient forms | Focal adhesion signaling |
| S100A16 mutants | Calcium-binding mutants | Astrocyte differentiation |
| FLNC mutants | Dimerisation mutants | Muscle disease |
How Is Hsp27 protein binding Regulated?
Hsp27 protein binding is regulated at multiple levels. Phosphorylation of Hsp27 by p38 MAPK is a key regulatory mechanism; for example, lysosomal damage triggers a p38 MAPK-dependent phosphorylation cascade that promotes lysophagy via Hsp27. Additionally, competing protein-protein interactions can displace Hsp27 from its clients, as shown for tau. The ubiquitin-proteasome system also intersects with Hsp27 function, as Hsp27 itself is a ubiquitin-binding protein involved in I-kappaBalpha degradation. Furthermore, Hsp27 binding to VDAC3 is modulated by ubiquitination, with Hsp27 impeding VDAC3 ubiquitination. These regulatory layers ensure that Hsp27 interactions are context-dependent and finely tuned.
Hsp27 protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSPB1 | Cancer chemoresistance, neurodegeneration | Knockout and overexpression in cancer cell lines |
| VDAC3 | Ferroptosis resistance in breast cancer | Point mutation of ubiquitination sites; knock-in |
| MAPT | Alzheimer's disease, tauopathies | Tau aggregation models with Hsp27 knockout |
| NFKBIA | Inflammation, cancer | Knockout of Hsp27 binding domain; NF-kappaB reporter |
| S100A16 | Astrocyte differentiation | Overexpression and knockout in multipotent cells |
Cancer and chemoresistance
Hsp27 protein binding is implicated in cancer progression and resistance to therapy. In HER2-low breast cancer, Hsp27 binds to VDAC3 and impedes its ubiquitination, alleviating ferroptosis and conferring resistance to trastuzumab deruxtecan. Additionally, Hsp27 binding to I-kappaBalpha promotes its degradation, activating NF-kappaB, which can drive tumorigenesis. These findings highlight Hsp27 interactions as potential therapeutic targets.
Neurodegenerative diseases
In neurodegeneration, Hsp27 binding to tau regulates tau aggregation. Competing protein-protein interactions control this binding, and disruption can lead to tau pathology characteristic of Alzheimer's disease. Modulating Hsp27-tau interaction may offer a therapeutic strategy.
Mitochondrial dysfunction and metabolic stress
Hsp27 controls mitochondrial function by modulating ceramide generation. Dysregulation of this binding can affect cell survival and metabolism, linking Hsp27 to metabolic disorders.
Inflammatory signaling
By binding to I-kappaBalpha, Hsp27 influences NF-kappaB activation, a master regulator of inflammation. This interaction connects Hsp27 to inflammatory diseases and suggests that targeting Hsp27 binding could modulate inflammatory responses.
From Hsp27 protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Hsp27 binding to tau affect aggregation? | HSPB1 knockout in neuronal cells expressing tau |
| Is phosphorylation required for Hsp27-lysophagy? | Point mutation of Hsp27 phosphorylation sites |
| Does Hsp27 binding to VDAC3 require ubiquitination? | Knock-in of ubiquitin-deficient VDAC3 |
| What is the interactome of Hsp27? | Tagged knock-in of Hsp27 for AP-MS |
| Can Hsp27 overexpression rescue stress? | Overexpression of wild-type vs. mutant Hsp27 |
| Does Hsp27 binding to I-kappaBalpha regulate NF-kappaB? | Knockout of Hsp27 in immune cells |
How to Study the Hsp27 protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between Hsp27 and client | Identify novel binding partners |
| Mass spectrometry | Protein composition of Hsp27 complexes | Interactome profiling |
| CRISPR knockout | Loss-of-function of Hsp27 or clients | Determine causal role in binding |
| Phospho-specific antibodies | Phosphorylation status of Hsp27 | Study regulation by p38 MAPK |
| FRET/BiFC | Real-time interaction dynamics | Visualize binding in live cells |
| Tau aggregation assay | Aggregation of tau in presence of Hsp27 | Neurodegeneration research |
| Ferroptosis assay | Cell death upon ferroptosis induction | Cancer drug resistance |
| NF-kappaB reporter | NF-kappaB transcriptional activity | Inflammation and cancer |
Co-immunoprecipitation and mass spectrometry
Co-immunoprecipitation (co-IP) followed by mass spectrometry is a standard method to identify Hsp27 binding partners. For example, Jia et al. used co-IP to identify hic-5/ARA55 as an Hsp27 binding protein. This approach can be coupled with quantitative proteomics to compare binding under different conditions.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes that modulate Hsp27 protein binding. For instance, knocking out HSPB1 can reveal its role in ferroptosis and drug resistance. Libraries targeting kinases can uncover regulators of Hsp27 phosphorylation.
Proximity labeling and imaging
Proximity labeling techniques such as BioID or APEX can map Hsp27 interactors in living cells. Fluorescence resonance energy transfer (FRET) and bimolecular fluorescence complementation (BiFC) can visualize Hsp27-client interactions in real time.
Functional assays
Functional assays such as tau aggregation assays, NF-kappaB reporter assays, and ferroptosis sensitivity tests are used to assess the consequences of Hsp27 binding. These assays often employ CRISPR-engineered cell lines with specific mutations.
How CRISPR Can Be Used to Study GO:0051008 Hsp27 protein binding
Knockout
CRISPR knockout of HSPB1 (Hsp27) or its client genes is used to abolish Hsp27 protein binding and assess downstream effects. For example, HSPB1 knockout can reverse VDAC3-mediated ferroptosis resistance in breast cancer cells. Knockout of client genes such as MAPT can reveal the importance of Hsp27-tau interaction.
Point Mutation
Point mutations can be introduced into Hsp27 phosphorylation sites (e.g., Ser15, Ser78, Ser82) to study how phosphorylation regulates binding. For instance, phospho-deficient mutants can block lysophagy. Similarly, point mutations in client proteins can disrupt specific binding interfaces.
Knock-in
Knock-in of tagged Hsp27 (e.g., GFP, HA, or BioID) allows for affinity purification and proximity labeling to identify binding partners in a physiological context. Knock-in of disease-associated mutations in clients can model altered Hsp27 binding.
Overexpression
Overexpression of wild-type or mutant Hsp27 can be used to test gain-of-function effects on client proteins. For example, overexpression of Hsp27 can protect cells from stress, while overexpression of binding-deficient mutants can act as dominant negatives.
How EDITGENE Supports Hsp27 protein binding Research
Researchers studying Hsp27 protein binding-related genes often need to determine whether a candidate gene is causally involved in the interaction or its downstream effects. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation of Hsp27 interactions.
Contact EDITGENE today to design your custom CRISPR model for Hsp27 protein binding research.
Frequently Asked Questions About Hsp27 protein binding
What is Hsp27 protein binding?
Hsp27 protein binding (GO:0051008) is the molecular function of selectively interacting with Hsp27, a small heat shock protein, to modulate client protein stability and function.
What genes are involved in Hsp27 protein binding?
Key genes include HSPB1 (Hsp27), MAPT (tau), NFKBIA (I-kappaBalpha), VDAC3, HIC5, and S100A16.
How is Hsp27 protein binding regulated?
It is regulated by phosphorylation of Hsp27, particularly by p38 MAPK, and by competing protein-protein interactions.
What diseases are associated with Hsp27 protein binding?
Cancer chemoresistance, neurodegenerative diseases like Alzheimer's, and inflammatory disorders.
What methods are used to study Hsp27 protein binding?
Co-immunoprecipitation, mass spectrometry, CRISPR knockout, FRET, and functional assays.
Can CRISPR be used to study Hsp27 protein binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect Hsp27 interactions.
What is the role of Hsp27 binding to tau?
Hsp27 binding to tau competes with other proteins and regulates tau aggregation, relevant to Alzheimer's disease.
How does Hsp27 binding affect cancer drug resistance?
Hsp27 binding to VDAC3 impedes its ubiquitination, alleviating ferroptosis and conferring resistance to trastuzumab deruxtecan.
What is the relationship between Hsp27 and I-kappaBalpha?
Hsp27 binds to I-kappaBalpha and promotes its proteasomal degradation, activating NF-kappaB.
How can EDITGENE help with Hsp27 protein binding research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study Hsp27 interactions.
Conclusion
Hsp27 protein binding (GO:0051008) is a multifaceted molecular function that underpins cellular stress responses, protein homeostasis, and disease pathogenesis. Its interactions with clients such as tau, I-kappaBalpha, and VDAC3 have been implicated in neurodegeneration, cancer, and inflammation. Understanding the regulation and consequences of these interactions requires robust experimental models. CRISPR-based approaches, combined with proteomics and imaging, offer powerful means to dissect Hsp27 protein binding. EDITGENE's services can accelerate such research by providing custom-engineered cell lines and screening platforms.
References
- 1. Cheng YC et al.. 2022. Downregulated Calcium-Binding Protein S100A16 and HSP27 in Placenta-Derived Multipotent Cells Induce Functional Astrocyte Differentiation.. Stem Cell Rev Rep 18(2):839-852 PMID: 35061207
- 2. Zou Y et al.. 2024. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer.. Drug Resist Updat 77:101126 PMID: 39243601
- 3. Freilich R et al.. 2018. Competing protein-protein interactions regulate binding of Hsp27 to its client protein tau.. Nat Commun 9(1):4563 PMID: 30385828
- 4. Parcellier A et al.. 2003. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.. Mol Cell Biol 23(16):5790-802 PMID: 12897149
- 5. Boyd RA et al.. 2023. The heat shock protein Hsp27 controls mitochondrial function by modulating ceramide generation.. Cell Rep 42(9):113081 PMID: 37689067
- 6. Gallagher ER et al.. 2024. Lysosomal damage triggers a p38 MAPK-dependent phosphorylation cascade to promote lysophagy via the small heat shock protein HSP27.. Curr Biol 34(24):5739-5757.e8 PMID: 39541976
- 7. Jia Y et al.. 2001. Identification and characterization of hic-5/ARA55 as an hsp27 binding protein.. J Biol Chem 276(43):39911-8 PMID: 11546764
- 8. Wang Z et al.. 2025. Filamin C dimerisation is regulated by HSPB7.. Nat Commun 16(1):4090 PMID: 40312381
